Loading...

PODCAST

Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit

health & fitness medicine

All Episodes

19:21

WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/10/05

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026.We dived into five pivotal studies, including: MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary ADAURA Update: 8-year update continues to show benefit of adjuvant

en

21:57

Managing Toxicities of HER2+ Therapies in Upper GI...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/30

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn. Join us as we discussed: The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions Addressing different dose used for

en

26:05

Upper GI Treatment Algorithm (Esophageal, Gastric,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/28

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.During our discussion we touched on: The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local

en

22:38

Follicular & Mantle Cell Lymphoma Treatment...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/24

In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma.Join us as we explored: The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches The evolving role of

en

21:12

Diffuse Large B-cell Lymphoma (DLBCL) Treatment...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/22

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in

en

26:55

Revolution Medicines CEO Dr. Mark Goldsmith:...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/21

Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient

en

20:54

Camizestrant + CDK 46i FDA Approval in Hormone...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/16

Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval,

en

22:51

SURPASS-ET: FDA Approval of Ropeginterferon alfa-2b...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/14

Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV).The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon

en

24:03

Myelofibrosis Treatment Algorithm Discussion: Dr....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/07

Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.Join us as we explored: The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of

en

26:47

Managing Toxicities of Therapies in Polycythemia Vera...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/04

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer

en

19:44

VERIFY: FDA Approval of Rusfertide in Polycythemia...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/09/02

Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.Key topics discussed included: The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron

en

28:35

Polycythemia vera (PV) and Essential thrombocythemia...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/31

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).Join us as we delved into: The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels The role of bone marrow biopsies in diagnosing and

en

21:59

Multiple Myeloma Management - Partners in Practice...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/27

Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari, a myeloma specialist, nurse practitioner Samantha Shenoy, NP, and clinical nurse Jenny Truong, RN.In this insightful discussion, we covered: The current standard of care for newly diagnosed multiple myeloma patients, focusing on quadruple therapy The role

en

16:07

HERIZON-GEA-01: FDA Approval of Zanidatamab +...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/25

We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical

en

25:40

Rapid Fire Rounds - Multiple Myeloma Management with...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/24

Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management. The panel covers: Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from

en

20:49

EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/20

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma.Join us as we dive into: The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide What makes cereblon modulators different from

en

24:30

Managing Toxicities of Androgen Receptor Pathway...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/17

Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.Key topics

en

25:00

Challenging Cases in Myelodysplastic Syndrome (MDS) -...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/13

Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression.In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating

en

27:42

Treatment Algorithm of Myelodysplastic Syndrome (MDS)...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/10

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS).We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment

en

19:04

Pancreatic Cancer Management - Partners in Practice...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/06

Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer.In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Klein, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the

en

289 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Healthy Chat

DR ALI BANIHAMOUR

Dingue ‐ RTS

RTS - Radio Télévision Suisse

Words of Wellness with Shelly

Shelly Jefferis

Linchpin Conversations

Pat Sherwood